Pfizer signs development deal with Protalix

Courtesy Newsvine - business  Tue, 12/01/2009 - 05:56

Drug developer Pfizer Inc. is paying Protalix BioTherapeutics Inc. $60 million upfront for licensing rights to a developing Gaucher's disease treatment, the companies said on Tuesday.


 

Related items

Pfizer extends Icagen stock tender offer by a day
Drugmaker Pfizer Inc. is extending by a day its tender offer for pain drug developer Icagen, after the number of shares tendered by Wednesday's deadline fell just short of what Pfizer needed.

Pfizer boosts dividend 11 percent
Drug developer Pfizer Inc. says its board of directors boosted the quarterly dividend 11 percent.

Pfizer to pay $14.5M to settle marketing charges
A federal prosecutor says the drugmaker Pfizer Inc. has agreed to pay the government $14.5 million to settle charges it illegally marketed its drug for a condition called an overactive...

Panasonic BB-GT1540B Globarange Expandable Cordless...
The GLOBARANGE 2-line hybrid calling system, winner of Electronic House magazine's 2007 Product of the Year award, is the last phone you'll ever have to buy. Make calls as you want:...

Panasonic Dect 6.0 Expandable Silver Digital Cordless...
DECT 6.0 TECHNOLOGY EXPANDABLE UP TO 6 HANDSETS ALL DIGITAL ANSWERING SYSTEM WHITE BACKLIT LCD ON HANDSET CALL WAITING CALLER ID WITH TALKING CALLER ID UP TO 4-WAY CONFERENCE CAPABILITY NIGHT...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
CAPTCHA
We apologize for the inconvenience. Please help fight spam.
business.marc8.com